Drug Profile

Abciximab biosimilar - Primrose Bio

Alternative Names: Monoclonal antibody 7E3 - Primrose Bio

Latest Information Update: 22 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfenex
Developer Primrose Bio
Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
Mechanism of Action GPIIb-IIIa antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
01 Jan 2015 No development reported for Vascular disorders in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com